When Scans Stay Stable: How Progression‑Free Survival Reflects Survival in mCRPC

At the 2026 American Urological Association (AUA) Annual Meeting, researchers showed that radiographic progression‑free survival (rPFS), the time from treatment start until scans show clear cancer progression or death, is a strong and meaningful reflection of overall survival in men with metastatic castration‑resistant prostate cancer (mCRPC). Using individual‑patient data from the large TALAPRO‑2 trial, they found that rPFS closely tracks how long patients live, not just how their scans look.

TALAPRO‑2 tested talazoparib plus enzalutamide versus placebo plus enzalutamide as first‑line treatment in mCRPC, enrolling both an unselected population and a homologous recombination repair (HRR)‑deficient group, including patients with BRCA1, BRCA2, and other DNA‑repair mutations. For this AUA analysis, investigators examined how strongly each patient’s rPFS predicted their overall survival using three statistical methods across multiple subgroups: overall mCRPC, HRR‑deficient, BRCA‑mutated, and patients without or with unknown mutations, as well as those with or without prior chemotherapy or hormone‑targeting drugs.

The results were remarkably consistent. Across almost all groups, the correlation between rPFS and overall survival was moderate to strong, with many values above 0.7, a threshold often considered “strong” in statistics. In the overall unselected group it was about 0.82, in the HRR‑deficient group about 0.77, and in BRCA‑mutated patients about 0.73. Even in subgroups without detectable HRR or BRCA mutations or with prior treatments, the relationship stayed solid, with only one isolated subgroup showing a weaker correlation.

For patients and doctors, this means that when a new therapy improves rPFS, it is very likely also extending life, not just delaying a technical change on a scan. This gives clinicians more confidence in using imaging‑based results to guide treatment decisions and in interpreting trial outcomes. For regulators and drug developers, strong rPFS–survival correlation supports using rPFS as a primary endpoint in phase 3 trials, which can speed up approval of effective treatments without waiting years for full survival data.

Source.